Tudor Investment Corp ET AL Purchases Shares of 38,619 Liquidia Co. (NASDAQ:LQDA)

Tudor Investment Corp ET AL acquired a new position in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 38,619 shares of the company's stock, valued at approximately $454,000.

Several other hedge funds and other institutional investors have also made changes to their positions in LQDA. Steward Partners Investment Advisory LLC acquired a new position in shares of Liquidia during the fourth quarter valued at approximately $59,000. Summit Investment Advisors Inc. grew its position in Liquidia by 35.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after buying an additional 1,719 shares during the last quarter. EntryPoint Capital LLC acquired a new position in Liquidia in the fourth quarter worth approximately $154,000. KLP Kapitalforvaltning AS acquired a new position in Liquidia in the fourth quarter worth approximately $169,000. Finally, Arizona State Retirement System grew its position in Liquidia by 20.3% in the fourth quarter. Arizona State Retirement System now owns 15,888 shares of the company's stock worth $187,000 after buying an additional 2,685 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on LQDA. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a research note on Monday. Needham & Company LLC reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Liquidia in a research note on Monday. Scotiabank restated an "outperform" rating on shares of Liquidia in a research report on Monday, May 5th. Finally, Raymond James upped their target price on Liquidia from $27.00 to $29.00 and gave the company a "strong-buy" rating in a report on Friday, May 9th. One analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Liquidia has a consensus rating of "Buy" and an average price target of $27.13.

Insider Buying and Selling

In related news, insider Rajeev Saggar sold 2,450 shares of the firm's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $13.67, for a total transaction of $33,491.50. Following the sale, the insider now directly owns 263,152 shares in the company, valued at $3,597,287.84. This trade represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jason Adair sold 1,856 shares of the company's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $25,185.92. Following the completion of the transaction, the insider now directly owns 184,304 shares of the company's stock, valued at approximately $2,501,005.28. The trade was a 1.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,138 shares of company stock worth $450,233 in the last 90 days. 30.10% of the stock is owned by company insiders.

Liquidia Stock Up 10.1%

LQDA stock traded up $1.62 during mid-day trading on Wednesday, reaching $17.61. 1,099,260 shares of the stock traded hands, compared to its average volume of 1,006,667. Liquidia Co. has a 52 week low of $8.26 and a 52 week high of $17.80. The firm has a market capitalization of $1.51 billion, a PE ratio of -10.80 and a beta of 0.24. The business has a 50-day moving average of $14.25 and a two-hundred day moving average of $13.21.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The firm had revenue of $3.12 million for the quarter, compared to analyst estimates of $3.23 million. On average, equities research analysts anticipate that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).